Sun Yat-Sen

The diagnostic utility of prostate biopsy is limited for prostate cancer (PCa) in the prostate-specific antigen (PSA) grey zone. This study aims to evaluate the diagnostic performance of multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for PSA grey zone PCa and clinically significant PCa (csPCa). A total of 82 patients with PSA levels ranging from 4 to 10 ng/mL who underwent 18F-PSMA-1007 PET/CT, mpMRI, and prostate biopsy were prospectively enrolled. For 18F-PSMA-1007 PET/CT and mpMRI in detecting PCa and csPCa, sensitivity, specificity, and area under the curve (AUC) were assessed using biopsy histology as the standard. 18F-PSMA-1007 PET/CT demonstrated better diagnostic performance for PCa than mpMRI (AUC 0.81 vs. 0.63, P = 0.02). 11.0% of patients with PI-RADS 3-5 had no PCa on biopsy, of whom 77.8% were correctly differentiated by 18F-PSMA-1007 PET/CT. Combined 18F-PSMA-1007 PET/CT + mpMRI improved sensitivity (92.5% vs. 73.6%) and negative predictive value (NPV, 78.9% vs. 53.3%) compared with mpMRI alone. 18F-PSMA-1007 PET/CT outperformed mpMRI for detecting PCa in the grey zone level of PSA. 18F-PSMA-1007 PET/CT in combination with mpMRI has additional improvement in sensitivity and NPV for csPCa detection. Clinical Trial Registration: NCT05958004, 2024-07.

Abstract Genes discovered by previous epigenetic studies of schizophrenia have focused solely on diagnostics or pathology, potentially leading to a disconnection between them.

Abstract Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy and the most common form of non-Hodgkin lymphoma (NHL) that occurs worldwide.

Recent findings on electrocatalysis promoted by alkali metal ions (AM+) have challenged the prevailing consensus that AM+ are chemically inert spectators. Now, theoretical and experimental evidence of an AM+-coupled reaction intermediate contribute to confirming the catalytic role of AM+ in electrochemical processes.

Virome-scale studies are changing our understanding of the virosphere, but deficiencies in reporting may limit the value of these studies. To increase the usefulness of virome-scale studies, 10 recommendations for the improvement of reporting are provided.

Abstract Lipid metabolism disorder is a critical feature of Crohn's disease (CD). Phosphatidylinositol (PI) and its derivative, phosphatidylinositol bisphosphate (PIP2), are associated with CD.

Abstract Pathogens significantly influence natural and agricultural ecosystems, playing a crucial role in the regulation of species populations and maintaining biodiversity.

Abstract Recent advancements in Large Language Models (LLMs) suggest imminent commercial applications of such AI systems which serve as

This cohort study of 5775 adults included 2881 women (weighted proportion, 52.6%) and 2894 men (weighted, 47.4%), with a weighted mean (SE) age of 56.6 (0.4) years. RMA were present in 1251 participants (weighted, 17.9%), of whom 710 (weighted, 9.8%) had retinopathy, 635 (weighted, 9.3%) had AVN, 64 (weighted, 1.0%) had FAN, and 21 (weighted, 0.3%) had HP. During a median of 12.2 years (range, 0.1–15.0 years) of follow-up, 1488 deaths occurred, including 452 associated with cardiovascular disease (CVD), 341 associated with cancer, and 695 associated with other causes. After adjusting confounding factors, the presence of any RMA and retinopathy at baseline was associated with higher risk of all-cause mortality (HR, 1.26; 95%CI, 1.07–1.47; HR, 1.36; 95%CI, 1.09–1.71, respectively), CVD mortality (HR, 1.36; 95%CI, 1.06–1.73; HR, 1.53; 95%CI, 1.04–2.26, respectively) and other-cause mortality (HR, 1.33; 95%CI, 1.06–1.67; HR, 1.55; 95%CI, 1.20–2.01, respectively). Additionally, FAN was significantly associated with an increased risk of other-cause mortality (HR, 2.06; 95%CI, 1.16–3.65). Although AVN was not associated with mortality in the whole population, it was significantly related to higher risks of all-cause and CVD death in those with obesity (HR, 1.68; 95%CI, 1.12–2.52; HR, 1.96; 95%CI, 1.23–3.13, respectively).

Background and objectives There is a growing demand for dementia care to be funded by long-term care insurance (LTCI). However, evidence